Comparing Biolase (NASDAQ:BIOL) and Henry Schein (HSIC)

Biolase (NASDAQ: BIOL) and Henry Schein (NASDAQ:HSIC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

How to Become a New Pot Stock Millionaire

36.2% of Biolase shares are owned by institutional investors. Comparatively, 98.3% of Henry Schein shares are owned by institutional investors. 3.2% of Biolase shares are owned by company insiders. Comparatively, 1.2% of Henry Schein shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Biolase and Henry Schein’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biolase -35.91% -67.04% -39.50%
Henry Schein 3.26% 19.70% 7.80%

Volatility & Risk

Biolase has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, Henry Schein has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Biolase and Henry Schein, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biolase 0 0 1 0 3.00
Henry Schein 1 8 9 0 2.44

Biolase currently has a consensus target price of $2.50, indicating a potential upside of 614.29%. Henry Schein has a consensus target price of $82.31, indicating a potential upside of 15.82%. Given Biolase’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Biolase is more favorable than Henry Schein.

Earnings and Valuation

This table compares Biolase and Henry Schein’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biolase $46.93 million 0.76 -$16.85 million N/A N/A
Henry Schein $12.46 billion 0.88 $406.29 million $3.60 19.74

Henry Schein has higher revenue and earnings than Biolase.


Henry Schein beats Biolase on 8 of the 12 factors compared between the two stocks.

About Biolase

BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine in the United States and internationally. The company offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. Its dental imaging products comprise 3Shape Trios intraoral scanner and digital impression systems for high-speed digital 3-D picture taking; Galaxy BioMill CAD/CAM system that enables dental practitioners to design, scan, mill, and finish crowns, inlays, and veneers inside the dental office; and CEFLA NewTom VGi and VG3 3-D cone beam computed tomography devices. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

About Henry Schein

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides animal health products, such as branded and generic pharmaceuticals, surgical and consumable products and services, and equipment; and medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners, and animal health clinics. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. The company was founded in 1932 and is headquartered in Melville, New York.

Receive News & Ratings for Biolase Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase and related companies with's FREE daily email newsletter.

Leave a Reply